Abbott ABT recently received a CE Mark in Europe for the AVEIR dual chamber (DR) leadless pacemaker system, the first ever dual chamber leadless pacemaker that treats people with abnormal or slow ...

The US Food and Drug Administration has approved a dual-chamber leadless pacemaker system with implant-to-implant communication, according to Abbott. The Aveir DR consists of two devices, one that is ...

NEW ORLEANS, May 20, 2023 /PRNewswire/ -- Abbott today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to ...

The Aveir VR pacemaker is implanted inside the heart’s right ventricle in a minimally invasive procedure following an assessment by the system of the heart’s electrical signals to determine its ideal ...

The FDA has approved Abbott Laboratories' ABT AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system to treat abnormal or slow heart rhythms. Through ...

Abbott (NYSE:ABT) said it has received FDA approval for its dual-chamber leadless pacemaker system Aveir DR for the treatment of slow or abnormal heart rhythms. The medical device maker said the ...

Last week, Abbott began the commercial launch of its new leadless pacemaker, which it believes is a historic development in the world of cardiac rhythm devices. Aveir DR is a better option than ...

Please provide your email address to receive an email when new articles are posted on . Abbott announced that the FDA has approved its Aveir VR single-chamber leadless pacemaker for the treatment of ...

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker The study successfully met all three of ...